Triple-negative breast cancer (TNBC), a clinically aggressive subtype, is characterized by the absence of key receptors—specifically estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) (Patel et al., 2024). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.